• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Marillyn Hewson Joins Chevron’s Board of Directors

    12/2/20 4:30:00 PM ET
    $JNJ
    $CVX
    $LMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Integrated oil Companies
    Energy
    Get the next $JNJ alert in real time by email

    SAN RAMON, Calif.--(BUSINESS WIRE)--Chevron Corporation (NYSE: CVX) announced that Marillyn A. Hewson has been elected to Chevron’s board of directors, effective on January 1, 2021. She will serve on the Audit Committee of the Board.

    Hewson, 66, is executive chairman of Lockheed Martin Corporation. She served as Lockheed Martin’s chairman, president and chief executive officer from January 2014 to June 2020 and held the positions of president and chief executive officer from January 2013 to December 2013.

    “It’s truly an honor to welcome Marillyn to Chevron’s board,” said Chevron Chairman and CEO Michael Wirth. “Marillyn is one of the world’s most accomplished business leaders. She brings valuable global business experience as well as decades of perspective on international commerce and geopolitics to our board, and will make our company better.”

    Hewson joined Lockheed Martin more than 35 years ago as an industrial engineer. During her career she has held leadership positions across the corporation. She currently serves on the board of directors of Johnson & Johnson, the Congressional Medal of Honor Foundation, the Board of Governors of the USO, and as chair of the Catalyst Board of Directors. Hewson has served on several U.S. government advisory bodies, including her current appointment to the American Workforce Policy Advisory Board. She earned her Bachelor of Science degree in business administration and her Master of Arts degree in economics from The University of Alabama and has completed executive development programs at Columbia Business School and Harvard Business School.

    Chevron Corporation is one of the world’s leading integrated energy companies. Through its subsidiaries that conduct business worldwide, the company is involved in virtually every facet of the energy industry. Chevron explores for, produces and transports crude oil and natural gas; refines, markets and distributes transportation fuels and lubricants; manufactures and sells petrochemicals and additives; generates power; and develops and deploys technologies that enhance business value in every aspect of the company’s operations. Chevron is based in San Ramon, Calif. More information about Chevron is available at www.chevron.com.

    Get the next $JNJ alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $JNJ
    $CVX
    $LMT

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    7/23/2025Hold → Buy
    Erste Group
    Lockheed Martin Corporation
    $LMT
    7/23/2025$440.00Buy → Hold
    Truist
    Lockheed Martin Corporation
    $LMT
    7/10/2025$480.00Buy → Hold
    TD Cowen
    Johnson & Johnson
    $JNJ
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    Chevron Corporation
    $CVX
    5/13/2025$158.00Buy → Hold
    HSBC Securities
    Chevron Corporation
    $CVX
    5/6/2025$130.00Buy → Sell
    DZ Bank
    Chevron Corporation
    $CVX
    5/5/2025$155.00 → $150.00Hold
    TD Cowen
    Chevron Corporation
    $CVX
    4/23/2025$124.00Neutral → Sell
    Redburn Atlantic
    More analyst ratings

    $JNJ
    $CVX
    $LMT
    SEC Filings

    See more
    • Chevron Corporation filed SEC Form 8-K: Leadership Update

      8-K - CHEVRON CORP (0000093410) (Filer)

      7/29/25 4:10:21 PM ET
      $CVX
      Integrated oil Companies
      Energy
    • Lockheed Martin Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - LOCKHEED MARTIN CORP (0000936468) (Filer)

      7/28/25 4:21:54 PM ET
      $LMT
      Military/Government/Technical
      Industrials
    • SEC Form 10-Q filed by Johnson & Johnson

      10-Q - JOHNSON & JOHNSON (0000200406) (Filer)

      7/24/25 4:04:24 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $CVX
    $LMT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      12/12/24 5:27:36 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $CVX
    $LMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Johnson & Johnson upgraded by Erste Group

      Erste Group upgraded Johnson & Johnson from Hold to Buy

      7/23/25 8:55:43 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lockheed Martin downgraded by Truist with a new price target

      Truist downgraded Lockheed Martin from Buy to Hold and set a new price target of $440.00

      7/23/25 7:39:07 AM ET
      $LMT
      Military/Government/Technical
      Industrials
    • Lockheed Martin downgraded by TD Cowen with a new price target

      TD Cowen downgraded Lockheed Martin from Buy to Hold and set a new price target of $480.00

      7/10/25 8:35:35 AM ET
      $LMT
      Military/Government/Technical
      Industrials

    $JNJ
    $CVX
    $LMT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • July 21, 2023 - FDA Roundup: July 21, 2023

      For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

      7/21/23 4:02:23 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

      For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

      5/5/22 4:51:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

      For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

      8/18/21 1:06:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $CVX
    $LMT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Boston Jury Hits Johnson & Johnson with Record $42M Verdict in Asbestos Baby Powder Case

      Dean Omar Branham Shirley attorneys secure verdict by linking mesothelioma to asbestos in J&J talc products A Boston jury has sided with Paul and Kathryn Lovell in a lawsuit against cosmetic behemoth Johnson & Johnson (NYSE:JNJ) that asserted Mr. Lovell's mesothelioma was directly caused by the company's iconic, asbestos-laced baby powder. The jury awarded $42,609,300, making it what lawyers believe to be the largest mesothelioma verdict in Massachusetts history. During the two-week trial, jurors heard compelling arguments from Dean Omar Branham Shirley attorneys Aaron Chapman and Danny Kraft, who detailed how Johnson & Johnson and its affiliated entities knowingly concealed for decades

      7/29/25 7:11:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • John B. Hess Joins Chevron's Board of Directors

      Chevron Corporation (NYSE:CVX) announced that John B. Hess has been appointed to Chevron's Board of Directors. Hess, 71, served as CEO of Hess Corporation from 1995 to 2025 and as Chairman from 1995 to 2013. He led the company through its strategic transformation from an integrated oil company into a focused global independent exploration and production company. "We are excited to welcome John Hess to Chevron's Board," said Mike Wirth, Chevron's Chairman and CEO. "John not only built a great company, he is a highly respected industry leader, and our Board will benefit from his global experience, relationships and expertise." "I am delighted to join Chevron's Board of Directors at such

      7/29/25 8:15:00 AM ET
      $CVX
      Integrated oil Companies
      Energy
    • Johnson & Johnson Launches VIRTUGUIDE™ AI-Powered Patient-Matched Lapidus System in U.S. to Reduce Complexity in Bunion Surgery for Millions

      Early VIRTUGUIDE™ surgeons report a 30-minute reduction in surgical time versus traditional treatment1,2,*,** WEST CHESTER, Penn., July 29, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) – Johnson & Johnson MedTech, a global leader in orthopaedic technologies and solutions, today announced the launch of the VIRTUGUIDE™ System. This AI-powered, patient-matched solution is designed to support Lapidus procedures2, a type of bunion surgery that helps realign the foot by joining two bones near the arch (the first metatarsal bone and the medial cuneiform).3 The system uses pre-operative planning software, developed in collaboration with PeekMed®, to assess each patient's bunion and make persona

      7/29/25 8:03:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $CVX
    $LMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman and CEO Wirth Michael K was granted 51 shares (SEC Form 4)

      4 - CHEVRON CORP (0000093410) (Issuer)

      7/22/25 9:59:40 PM ET
      $CVX
      Integrated oil Companies
      Energy
    • VP and General Counsel Pate R. Hewitt was granted 20 shares (SEC Form 4)

      4 - CHEVRON CORP (0000093410) (Issuer)

      7/22/25 9:54:57 PM ET
      $CVX
      Integrated oil Companies
      Energy
    • Vice President Booth Thomas Ryder was granted 5 shares (SEC Form 4)

      4 - CHEVRON CORP (0000093410) (Issuer)

      7/22/25 8:09:11 PM ET
      $CVX
      Integrated oil Companies
      Energy

    $JNJ
    $CVX
    $LMT
    Financials

    Live finance-specific insights

    See more
    • Lockheed Martin Reports Second Quarter 2025 Financial Results

      Sales of $18.2 billionRecorded pre-tax losses on programs of $1.6 billion and other charges of $169 million, which impacted earnings per share by $5.83Net earnings of $342 million, or $1.46 per share, including impacts of program losses and other chargesCash from operations of $201 million and free cash flow of $(150) millionReturned $1.3 billion of cash to shareholders through dividends and share repurchasesReaffirming 2025 guidance for sales and free cash flowBETHESDA, Md., July 22, 2025 /PRNewswire/ -- Lockheed Martin Corporation (NYSE:LMT) today reported second quarter 2025 sales of $18.2 billion, compared to $18.1 billion in the second quarter of 2024. Net earnings in the second quarter

      7/22/25 7:29:00 AM ET
      $LMT
      Military/Government/Technical
      Industrials
    • Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025

      Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2025 of $1.30 per share on the company's common stock. The dividend is payable on September 9, 2025 to shareholders of record at the close of business on August 26, 2025. The ex-dividend date is August 26, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely po

      7/16/25 6:25:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson Reports Q2 2025 Results; Raises 2025 Outlook

      2025 Second-Quarter reported sales growth of 5.8% to $23.7 Billion with operational growth of 4.6%* and adjusted operational growth of 3.0%* 2025 Second-Quarter reflects earnings per share (EPS) of $2.29 and adjusted EPS of $2.77 Significant new product pipeline progress including approval of IMAAVY for generalized myasthenia gravis, priority review for TAR-200, data for CARVYKTI overall survival and progression-free benefits in multiple myeloma, and continuation of the clinical trial for a general surgery robotic system, OTTAVA Strong operational performance and favorable foreign exchange results in Company increasing full year estimated reported sales5 guidance at the midpoint b

      7/16/25 6:20:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $CVX
    $LMT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Johnson & Johnson

      SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

      4/10/24 5:12:55 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

      SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

      2/13/24 5:07:58 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Chevron Corporation (Amendment)

      SC 13G/A - CHEVRON CORP (0000093410) (Subject)

      2/13/24 4:55:53 PM ET
      $CVX
      Integrated oil Companies
      Energy

    $JNJ
    $CVX
    $LMT
    Leadership Updates

    Live Leadership Updates

    See more
    • John B. Hess Joins Chevron's Board of Directors

      Chevron Corporation (NYSE:CVX) announced that John B. Hess has been appointed to Chevron's Board of Directors. Hess, 71, served as CEO of Hess Corporation from 1995 to 2025 and as Chairman from 1995 to 2013. He led the company through its strategic transformation from an integrated oil company into a focused global independent exploration and production company. "We are excited to welcome John Hess to Chevron's Board," said Mike Wirth, Chevron's Chairman and CEO. "John not only built a great company, he is a highly respected industry leader, and our Board will benefit from his global experience, relationships and expertise." "I am delighted to join Chevron's Board of Directors at such

      7/29/25 8:15:00 AM ET
      $CVX
      Integrated oil Companies
      Energy
    • Block Set to Join S&P 500

      NEW YORK, July 18, 2025 /PRNewswire/ -- Block Inc. (NYSE:XYZ) will replace Hess Corp. (NYSE:HES) in the S&P 500 effective prior to the opening of trading on Wednesday, July 23. S&P 500 and S&P 100 constituent Chevron Corp. (NYSE: CVX) has acquired Hess Corp in a deal that closed today, July 18. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name  Action Company Name Ticker GICS Sector July 23, 2025 S&P 500 Addition Block XYZ Financials July 23, 2025 S&P 500 Deletion Hess HES Energy For more information about S&P Dow Jones Indices, please visit www.spdji.com.  ABOUT S&P DOW JONES INDICES S&P Dow Jones Indi

      7/18/25 6:02:00 PM ET
      $CVX
      $HES
      $SPGI
      $XYZ
      Integrated oil Companies
      Energy
      Finance: Consumer Services
      Finance
    • Chevron Completes Acquisition of Hess Corporation

      Creates premier integrated oil & gas company Combines world-class assets, people and capabilities Drives industry-leading free cash flow growth and shareholder returns Chevron Corporation (NYSE:CVX) announced today that it has completed its acquisition of Hess Corporation (NYSE:HES) following the satisfaction of all necessary closing conditions, including a favorable arbitration outcome regarding Hess' offshore Guyana asset. The combined company has one of the most advantaged and differentiated portfolios in the industry, with leading positions in critical energy markets around the world and a high cash margin production profile. In addition, on July 17, 2025, the Federal Trade Co

      7/18/25 8:29:00 AM ET
      $CVX
      $HES
      Integrated oil Companies
      Energy